Advair Diskus is a combination inhaler that delivers fluticasone propionate and salmeterol for the treatment of asthma and chronic obstructive pulmonary disease. Pharmacodynamically fluticasone propionate acts as a synthetic corticosteroid that reduces airway inflammation by inhibiting phospholipase a2 and downstream cytokine production. Salmeterol functions as a long-acting beta2 agonist that causes bronchodilation by stimulating beta receptors and relaxing airway smooth muscle. The corticosteroid component provides anti-inflammatory effects that improve lung function and diminish the frequency of exacerbations. The agonist component offers sustained bronchodilation lasting at least twelve hours, facilitating easier airflow during daily activities. Together the two agents produce a synergistic effect that addresses both the inflammatory and bronchoconstrictive components of the diseases. Advair Diskus is administered twice daily via a dry-powder inhaler, allowing localized delivery directly to the respiratory tract. This targeted delivery enhances systemic efficacy while minimizing exposure of surrounding tissues to higher concentrations.

Advair Diskus is a fixed-dose inhaler that combines a synthetic corticosteroid with a long-acting b2-agonist for the management of chronic respiratory disease. The corticosteroid component fluticasone propionate exerts its anti-inflammatory effect by binding to the glucocorticoid receptor and suppressing the transcription of cytokines and adhesion molecules. The b2-agonist component salmeterol produces bronchodilation by stimulating b2-adrenergic receptors on airway smooth muscle and increasing intracellular cyclic amp levels. Together the two agents provide sustained control of airway inflammation and bronchospasm improving lung function and reducing the frequency of exacerbations. Pharmacologically fluticasone's high lipophilicity allows retention in pulmonary tissue extending its anti-inflammatory action over 24 hours. Salmeterol's long side-chain anchors it to the receptor and slows its dissociation maintaining bronchodilation for up to 12 hours per dose.

Advair Diskus is a combination inhaler used for long-term asthma and copd treatment. Possible side effects include throat irritation and hoarseness. Some users may develop oral yeast infections if proper mouth rinsing is not performed. In rare cases cardiovascular effects such as increased heart rate have been reported. Muscle tremors and headaches are also documented adverse reactions. These effects are generally mild and often resolve with continued use but should be monitored.

Some users experience mild throat irritation after inhalation. A small number report occasional hoarseness that usually resolves with continued use. Dry mouth is listed as a possible side effect of the medication. Headache may occur, particularly in patients who are sensitive to aerosol particles. Tremor or shakiness of the hands has been observed in a minority of users. In rare cases muscle cramps or urinary tract infection have been reported.